Merck & Co., Inc.'s Stock Price Rises Amid Better-Than-Expected Q2 Results
Merck & Co., Inc.'s stock price rose 0.3% on Thursday, August 5th, after the company reported better-than-expected second-quarter results. The firm's adjusted loss of $0.13 per share was narrower than the expected $0.26 loss.
Dynamic Advisor Solutions LLC increased its holdings in Merck & Co., Inc. by 56.8% during the second quarter, according to a recent filing with the Securities and Exchange Commission. The firm now owns 64,313 shares of the company's stock worth approximately $8.264 million as of its most recent filing.
Merck & Co., Inc.'s revenue grew 5.1% year over year in the second quarter, reaching $16.61 billion. The company's newer products and pipeline programs supported its performance, with Keytruda remaining a primary growth driver at $8.37 billion in quarterly sales.
Merck & Co., Inc.'s 2026 revenue outlook was raised to $66.3 billion-$67.3 billion, reflecting confidence in Keytruda's commercial reach and pipeline progress. The company also reported a mixed development update for its anti-TL1A drug tulisokibart, which was discontinued in one rare lung-disease indication.